Lescol® XL effectively manages all major lipid parameters

June 26, 2000

The Novartis Pharmaceutical Corporation investigational compound Lescol® XL (fluvastatin sodium extended release tablets) shows significant reductions in LDL-C and excellent increases in HDL-C, according to study results presented today at the 12th International Symposium on Atherosclerosis in Stockholm. The Phase III study data demonstrated a median decrease of 38 percent in LDL-C (low density lipoprotein cholesterol) and a mean increase of up to 18.7 percent in HDL-C (high density lipoprotein cholesterol) with Lescol® XL in patients with dyslipidemia. These results mean that Lescol® XL effectively manages dyslipidemia since a previous meta analysis showed that a mean LDL-C reduction of 30 percent or less is sufficient to bring more than 90 percent patients to the treatment goal.

Almost 70 percent of coronary heart disease patients have low HDL-C. These patients carry an increased risk of cardiovascular events of almost 40 percent. Hence the increase of up to 18.7 percent in HDL-C yielded by Lescol® XL is clinically meaningful.

The data confirmed that Lescol® XL 80 mg provides significantly improved efficacy with a similar safety profile when compared to Lescol® (fluvastatin sodium) 40 mg. In phase II and III trials in a total of 900 patients treated with Lescol® XL, no cases of myopathy and rhabdomyolysis have been reported to date.
To learn more about Lescol® XL, contact Anna Frable, 973-781-5388, anna.frable@pharma.novartis.com of Novartis or Stacey Collins, 212-601-8360, scollins@pharma.novartis.com of Porter Novelli.

Porter Novelli

Related Cardiovascular Events Articles from Brightsurf:

The Lancet: Older adults are at greater risk of cardiovascular events than younger people, and benefit at least as much from cholesterol-lowering medications, two studies suggest
Peer-reviewed / 1 Observational study + 1 Systematic review and meta-analysis / People

Patients with intermediate left main disease experience worse cardiovascular events
A new study shows that when compared with patients without intermediate left main coronary artery disease, those with intermediate left main disease have greater risk of cardiovascular events.

Genetic testing for antiplatelet therapy post-PCI misses cut in cardiovascular events
An international clinical trial that used genetic testing to guide which antiplatelet medication was given to patients following percutaneous coronary intervention (PCI) did not meet its stated goal for cutting in half the incidence of serious adverse cardiovascular events, such as heart attack and stroke, in the year following the procedure, according to study results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Analysis predicts purified fish oil could prevent thousands of cardiovascular events
Researchers from the University of California, Irvine have conducted a statistical analysis that predicts more than 70,000 heart attacks, strokes and other adverse cardiovascular events could be prevented each year in the U.S. through the use of a highly purified fish oil therapy.

Automated CT biomarkers predict cardiovascular events better than current practice
Researchers at the NIH and University of Wisconsin demonstrated that using artificial intelligence to analyze CT scans can produce more accurate risk assessment for major cardiovascular events than current, standard methods such as the Framingham risk score and body-mass index.

Irregular sleep may increase risk of cardiovascular events
A new study led by investigators from Brigham and Women's Hospital measured participants' sleep duration and timing, finding that over a five-year period, individuals who had the most irregular sleep experienced a two-fold increased risk of developing cardiovascular disease compared to those with the most regular sleep patterns.

Hot flashes shown to be linked to increased risk of later cardiovascular disease events
Previous studies suggested an association between hot flashes and cardiovascular (CVD) disease.

Fat mass index, not BMI, associated with cardiovascular events in people with diabetes
In people with diabetes, fat mass index, not body mass index (BMI), is associated with a higher risk of cardiovascular events, according to new research in CMAJ (Canadian Medical Association Journal).

Comparing major adverse cardiovascular events among patients with diabetes, reduced kidney function treated with metformin or sulfonylurea
This observational study compared major cardiovascular events (including hospitalization for heart attack, stroke, transient ischemic attack or cardiovascular death) among patients with diabetes and reduced kidney function treated with metformin or a sulfonylurea (a class of drugs to treat diabetes).

Familial hypercholesterolemia patients at high risk for cardiovascular events
Individuals with familial hypercholesterolemia (FH) were able to lower their cholesterol under FH specialty care, but many are still not meeting LDL-cholesterol targets, according to the FH Foundation's CASCADE FH® Registry.

Read More: Cardiovascular Events News and Cardiovascular Events Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.